MoonLake Immunotherapeutics, a clinical-stage company focused on SLK—a tri-specific Nanobody targeting IL-17A/F for inflammatory skin and joint diseases—is entering a pivotal phase marked by recent positive Phase 2 data and ongoing Phase 3 trials. The firm’s revenues remain nil, reflecting its development-stage status, with expenses surging due to extensive R&D programs and preparative commercial activities. MoonLake’s strong liquidity position benefits from a sizable loan facility, though missed Phase 3 milestones have delayed tranche draws. Watch for upcoming regulatory filings and trial readouts that will determine near-term financing and commercialization progress.